NEW YORK (GenomeWeb News) – Bioanalytical firm Protea Biosciences today announced four distribution deals.

The Morgantown, W.Va.-based company said that it has inked deals with Yair Technologies for the distribution of Protea products in Israel; with BioAnalytic covering Poland; with Irida Iberica covering Spain and Portugal; and with IDL Teknolojik covering Turkey.

The partners will distribute Protea's sample preparation and mass spectrometry products and its LAESI DP-1000 sample analysis instrument, Protea Vice President and General Manager Alessandro Baldi said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.